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1. INTRODUCTION {#jcla23251-sec-0005}
===============

Wilms tumor is a common embryonal kidney that mostly affects children.[1](#jcla23251-bib-0001){ref-type="ref"} It is typically characterized by the disorganized and dysregulated development of a kidney.[2](#jcla23251-bib-0002){ref-type="ref"}, [3](#jcla23251-bib-0003){ref-type="ref"} The prevalence of Wilms tumor is about 7‐10 per million in Western countries, while it is only 3.3 per million in China.[2](#jcla23251-bib-0002){ref-type="ref"}, [4](#jcla23251-bib-0004){ref-type="ref"} Nearly 95% of cases are diagnosed under ten years old, with mean diagnosis age at 43‐48 months.[5](#jcla23251-bib-0005){ref-type="ref"} Survival rates of Wilms tumor in Western countries have reached over 90%,[6](#jcla23251-bib-0006){ref-type="ref"} while the survival rate for relapsed cases is much lower.[7](#jcla23251-bib-0007){ref-type="ref"}, [8](#jcla23251-bib-0008){ref-type="ref"} What is more frustrated, survivors may be subject to chronic severe health conditions.[9](#jcla23251-bib-0009){ref-type="ref"} Strong evidence has been increasingly added in supporting the contribution of genetic variants to Wilms tumor. The *Wilms tumor 1* (*WT1*) gene, mapped to chromosome 11p13, was first identified in 1990 as a tumor suppressor gene in Wilms tumor.[10](#jcla23251-bib-0010){ref-type="ref"} Subsequently, mutations in the *WTX*, *CTNNB1*, and *TP53*, as well as abnormalities of 11p15 methylation have been discovered in Wilms tumor.[11](#jcla23251-bib-0011){ref-type="ref"}, [12](#jcla23251-bib-0012){ref-type="ref"}, [13](#jcla23251-bib-0013){ref-type="ref"}, [14](#jcla23251-bib-0014){ref-type="ref"}, [15](#jcla23251-bib-0015){ref-type="ref"} Apart from these, many other novel gene mutations also have been revealed to be involved in Wilms tumorigenesis.[16](#jcla23251-bib-0016){ref-type="ref"}, [17](#jcla23251-bib-0017){ref-type="ref"} However, all of the above gene mutations affects fewer than 50% of Wilms tumor cases.[18](#jcla23251-bib-0018){ref-type="ref"} Therefore, identifying more variants is indispensable in better understanding the Wilms tumor susceptibility.

N6‐methyladenosine (m^6^A) is the most prevalent and enriched mRNA post‐transcriptional modification.[19](#jcla23251-bib-0019){ref-type="ref"} First discovered in 1974, m^6^A modification is now found to be extensively spread in both prokaryotes and eukaryotes.[20](#jcla23251-bib-0020){ref-type="ref"} The m^6^A modification‐related enzymes are mainly composed of m^6^A methyltransferase ("writers": METTL3, METTL14, and WTAP), m^6^A demethylases ("erasers": FTO and ALKBH5), and m^6^A‐binding proteins ("readers": IGF2BP1 and YTHDF1).[21](#jcla23251-bib-0021){ref-type="ref"}, [22](#jcla23251-bib-0022){ref-type="ref"}, [23](#jcla23251-bib-0023){ref-type="ref"}, [24](#jcla23251-bib-0024){ref-type="ref"} The m^6^A modification plays a critical role in mRNA stability, mRNA translation, and many other important processes.[25](#jcla23251-bib-0025){ref-type="ref"} Dysregulated m^6^A is closely related to various diseases, especially cancers.[26](#jcla23251-bib-0026){ref-type="ref"}, [27](#jcla23251-bib-0027){ref-type="ref"}, [28](#jcla23251-bib-0028){ref-type="ref"} Genetic variants in the m^6^A genes may change the RNA sequences of the target sites or key flanking nucleotide and thereby influence m^6^A modification. The aberrant m^6^A modification level may have impacts on individuals' cancer susceptibility. The genetic variants in the m^6^A genes are referred to as the m^6^A‐associated SNPs (m^6^A‐SNPs).[29](#jcla23251-bib-0029){ref-type="ref"} The m^6^A modification has become a research hotspot yet studies on the association between m^6^A‐SNPs and cancer risk are very scarce. Therefore, it is urgent to explore the effect of m^6^A‐SNPs on cancer risk, which can provide a new perspective of not only the etiology of cancer but also of the role of m^6^A.

The roles of m^6^A modification gene *ALKBH5* SNPs were recently investigated in the risk of major depressive disorder,[30](#jcla23251-bib-0030){ref-type="ref"} rheumatoid arthritis,[31](#jcla23251-bib-0031){ref-type="ref"} and colorectal cancer.[32](#jcla23251-bib-0032){ref-type="ref"} Till now, no studies have explored the potential relationship of m^6^A modification gene *ALKBH5* SNPs with Wilms tumor risk. In this study, we conducted the first case‐control study of 414 Wilms tumor cases and 1199 controls to yield new insights into the role of m^6^A modification gene *ALKBH5* SNPs in Wilms tumorigenesis.

2. METHODS {#jcla23251-sec-0006}
==========

2.1. Study subjects {#jcla23251-sec-0007}
-------------------

Wilms tumor cases were enrolled from five hospitals located in Guangzhou, Zhengzhou, Wenzhou, Xi\'an, and Taiyuan, respectively.[33](#jcla23251-bib-0033){ref-type="ref"} The current study included a total of 414 cases and 1199 controls of Chinese ancestry, matched on age and gender (Table [S1](#jcla23251-sup-0001){ref-type="supplementary-material"}). All Wilms tumor cases were newly diagnosed and pathologically confirmed. No preoperative treatment such as chemotherapy or radiation was performed on the cases before the collection of the blood sample. Healthy controls were recruited in the same period and geographical region. We obtained written informed consent from all participants' parents or guardians prior to enrolment. Recruitment details and patient characteristics were available in the previously published study.[33](#jcla23251-bib-0033){ref-type="ref"} The study was approved by the Ethics Committee of Guangzhou Women and Children\'s Medical Center.

2.2. Genotyping {#jcla23251-sec-0008}
---------------

Potentially functional SNPs in *ALKBH5* were chosen from the dbSNP database following the criteria described in our previous studies.[34](#jcla23251-bib-0034){ref-type="ref"}, [35](#jcla23251-bib-0035){ref-type="ref"} Briefly, criteria were as follows: (a) located at the two ends of the *ALKBH5* gene (ie, the 5' near gene, 5' UTR, 3' UTR and 3' near gene); (b) the minor allele frequency (MAF) reported in 1000 Genomes (<https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/>) was ≥ 5% for Chinese Han subjects; and (c) affecting transcription factor binding sites (TFBS) activity or the miRNA binding sites activity. As a result, two SNPs (rs1378602 and rs8400) met these criteria. Genomic DNA was extracted from participants' blood. Samples were genotyped for the rs1378602 and rs8400 SNPs by a custom ABI 7900 HT Sequence Detection System (Applied Biosystems). For sample quality control, we introduced negative control without DNA templates in the genotyping analysis. Moreover, 10% of the samples were re‐genotyped for the SNPs to assess the genotyping error rate. All re‐genotyped SNPs achieved 100% concordance.

2.3. Statistical analysis {#jcla23251-sec-0009}
-------------------------

Characteristics of cases and controls were compared using the chi‐square test or *t* test as appropriate. Compliance of individual SNPs with the Hardy‐Weinberg equilibrium was measured in controls using a chi‐square test. To estimate the association of SNP with Wilms tumor risk, we conducted the unconditional logistic regression analysis. The odds ratios (ORs) and 95% confidence intervals (CIs) were used to determine the association. We also investigated the effect of *ALKBH5* gene SNPs on Wilms tumor susceptibility across strata of age, sex, and clinical stage. False‐positive report probability (FPRP) analysis was further explored to test whether the significant findings were just chance or noteworthy observations. All tests for statistical significance used a two‐sided *P* \< .05. Statistical analyses were completed in SAS 9.1 (SAS Institute Inc).

3. RESULTS {#jcla23251-sec-0010}
==========

3.1. Association between the *ALKBH5* SNPs and Wilms tumor risk {#jcla23251-sec-0011}
---------------------------------------------------------------

Patient characteristics were summarized in our previous publication.[33](#jcla23251-bib-0033){ref-type="ref"} The results of the correlation between *ALKBH5* gene polymorphisms and Wilms tumor susceptibility were presented in Table [1](#jcla23251-tbl-0001){ref-type="table"}. Finally, 413 cases and 1198 controls were successfully genotyped for rs1378602 and rs8400. The genotype frequencies of both SNPs were complied with the Hardy‐Weinberg equilibrium in control subjects (*P* = .488 for rs1378602 and *P* = .963 for rs8400). Neither of these two polymorphisms displayed a significant association with Wilms tumor risk. We then regarded rs1378602 AG/AA or rs8400 GG genotypes as protective genotypes to further explore the combined effects of the two SNPs. However, carriers with 1, 2, and 1‐2 protective genotypes did not have a lower risk in Wilms tumor than those without protective genotype.

###### 

Association between *ALKBH5* gene polymorphisms and Wilms tumor susceptibility

  Genotype                                                       Cases (N = 413)   Controls (N = 1198)   *P* [a](#jcla23251-note-0003){ref-type="fn"}   Crude OR (95% CI)   *P*    Adjusted OR (95% CI)[b](#jcla23251-note-0004){ref-type="fn"}   *P* [b](#jcla23251-note-0004){ref-type="fn"}
  -------------------------------------------------------------- ----------------- --------------------- ---------------------------------------------- ------------------- ------ -------------------------------------------------------------- ----------------------------------------------
  rs1378602 (HWE = 0.488)                                                                                                                                                                                                                         
  GG                                                             352 (85.23)       991 (82.72)                                                          1.00                       1.00                                                            
  AG                                                             59 (14.29)        195 (16.28)                                                          0.85 (0.62‐1.17)    .319   0.84 (0.61‐1.15)                                               .281
  AA                                                             2 (0.48)          12 (1.00)                                                            0.47 (0.11‐2.11)    .323   0.46 (0.10‐2.05)                                               .307
  Additive                                                                                               .188                                           0.82 (0.62‐1.10)    .188   0.81 (0.61‐1.09)                                               .160
  Dominant                                                       61 (14.77)        207 (17.28)           .238                                           0.83 (0.61‐1.13)    .238   0.82 (0.60‐1.12)                                               .205
  Recessive                                                      411 (99.52)       1186 (99.00)          .329                                           0.48 (0.11‐2.16)    .339   0.47 (0.10‐2.11)                                               .324
  rs8400 (HWE = 0.963)                                                                                                                                                                                                                            
  GG                                                             136 (32.93)       403 (33.64)                                                          1.00                       1.00                                                            
  AG                                                             205 (49.64)       583 (48.66)                                                          1.04 (0.81‐1.34)    .749   1.04 (0.81‐1.33)                                               .783
  AA                                                             72 (17.43)        212 (17.70)                                                          1.01 (0.72‐1.40)    .970   1.00 (0.72‐1.40)                                               .986
  Additive                                                                                               .911                                           1.01 (0.86‐1.19)    .911   1.01 (0.86‐1.18)                                               .933
  Dominant                                                       277 (67.07)       795 (66.36)           .792                                           1.03 (0.81‐1.31)    .793   1.03 (0.81‐1.30)                                               .825
  Recessive                                                      341 (82.57)       986 (82.30)           .904                                           0.98 (0.73‐1.32)    .904   0.98 (0.73‐1.32)                                               .905
  Protective genotypes[c](#jcla23251-note-0005){ref-type="fn"}                                                                                                                                                                                    
  0                                                              217 (52.54)       588 (49.08)                                                          1.00                       1.00                                                            
  1                                                              195 (47.22)       610 (50.92)                                                          0.86 (0.69‐1.08)    .209   0.86 (0.69‐1.08)                                               .200
  2                                                              1 (0.24)          0 (0.00)                                                             /                   /      /                                                              /
  1‐2                                                            196 (47.46)       610 (50.92)           .225                                           0.87 (0.70‐1.09)    .225   0.87 (0.69‐1.09)                                               .216

Abbreviations: CI, confidence interval; HWE, Hardy‐Weinberg equilibrium; OR, odds ratio.

chi‐square test for genotype distributions between Wilms tumor cases and cancer‐free controls.

Adjusted for age and gender.

Protective genotypes were carriers with rs1378602 AG/AA or rs8400 GG genotypes.

John Wiley & Sons, Ltd

3.2. Stratification analysis {#jcla23251-sec-0012}
----------------------------

We further performed a stratified analysis by age, gender and clinical stages (Table [2](#jcla23251-tbl-0002){ref-type="table"}). The protective effect of rs1378602 AG/AA genotypes was pronounced in the subgroup of children with clinical stage I diseases (adjusted OR = 0.56, 95% CI = 0.32‐0.98, *P* = .042). However, no significant association with Wilms tumor risk was found for the rs8400 in the stratification analysis. In subgroups of age \> 18 months, the existence of 1‐2 protective genotypes was associated with 0.74‐fold decreased risk of Wilms tumor, when compared to 0 protective genotypes (adjusted OR = 0.74, 95% CI = 0.56‐0.98, *P* = .035).

###### 

Stratification analysis of *ALKBH5* gene polymorphisms with Wilms tumor susceptibility

  Variables         rs1378602 (cases/controls)   AOR (95% CI)[a](#jcla23251-note-0007){ref-type="fn"}   *P* [a](#jcla23251-note-0007){ref-type="fn"}   rs8400 (cases/controls)   AOR (95% CI)[a](#jcla23251-note-0007){ref-type="fn"}   *P* [a](#jcla23251-note-0007){ref-type="fn"}   Protective genotypes (cases/controls)   AOR (95% CI)[a](#jcla23251-note-0007){ref-type="fn"}   *P* [a](#jcla23251-note-0007){ref-type="fn"}                                    
  ----------------- ---------------------------- ------------------------------------------------------ ---------------------------------------------- ------------------------- ------------------------------------------------------ ---------------------------------------------- --------------------------------------- ------------------------------------------------------ ---------------------------------------------- --------- ---------------------- ----------
  Age, month                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ≤18               118/377                      25/89                                                  0.90 (0.55‐1.47)                               .673                      53/147                                                 90/319                                         0.79 (0.54‐1.17)                        .245                                                   66/230                                         77/236    1.13 (0.77‐1.64)       .535
  \>18              234/614                      36/118                                                 0.78 (0.52‐1.16)                               .220                      83/256                                                 187/476                                        1.22 (0.90‐1.65)                        .199                                                   151/358                                        119/374   **0.74 (0.56‐0.98)**   **.035**
  Gender                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Females           166/417                      28/102                                                 0.69 (0.44‐1.09)                               .112                      61/172                                                 133/347                                        1.09 (0.76‐1.55)                        .654                                                   105/245                                        89/274    0.76 (0.54‐1.05)       .099
  Males             186/574                      33/105                                                 0.96 (0.63‐1.47)                               .856                      75/231                                                 144/448                                        0.99 (0.72‐1.37)                        .966                                                   112/343                                        107/336   0.97 (0.71‐1.31)       .837
  Clinical stages                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  I                 122/991                      15/207                                                 **0.56 (0.32‐0.98)**                           **.042**                  52/403                                                 85/795                                         0.81 (0.56‐1.17)                        .256                                                   70/588                                         67/610    0.92 (0.64‐1.31)       .638
  II                93/991                       23/207                                                 1.15 (0.71‐1.86)                               .576                      32/403                                                 84/795                                         1.31 (0.86‐2.00)                        .214                                                   61/588                                         55/610    0.87 (0.59‐1.27)       .459
  III               81/991                       13/207                                                 0.79 (0.43‐1.44)                               .438                      29/403                                                 65/795                                         1.17 (0.74‐1.84)                        .507                                                   52/588                                         42/610    0.77 (0.51‐1.18)       .229
  IV                40/991                       9/207                                                  1.09 (0.52‐2.29)                               .821                      13/403                                                 36/795                                         1.42 (0.75‐2.72)                        .284                                                   28/588                                         21/610    0.72 (0.40‐1.28)       .262
  I + II            215/991                      38/207                                                 0.81 (0.56‐1.18)                               .279                      84/403                                                 169/795                                        1.00 (0.75‐1.33)                        .995                                                   131/588                                        122/610   0.89 (0.68‐1.17)       .418
  III + IV          121/991                      22/207                                                 0.89 (0.55‐1.43)                               .620                      42/403                                                 101/795                                        1.24 (0.85‐1.82)                        .267                                                   80/588                                         63/610    0.76 (0.53‐1.07)       .115

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval.

The values that are 95% CIs excluded 1 or *P* \< .05 are indicated in bold.

Adjusted for age and gender, omitting the corresponding stratify factor.

John Wiley & Sons, Ltd

3.3. False‐positive report probability results {#jcla23251-sec-0013}
----------------------------------------------

We preset 0.2 as the FPRP threshold. As shown in Table [S2](#jcla23251-sup-0001){ref-type="supplementary-material"}, at the prior probability of 0.1, all of the significant findings disappeared. At a prior probability level of 0.25, the decreased Wilms tumor risk remains noteworthy in carriers with protective genotypes 1‐2 for the children \> 18‐month subgroup.

4. DISCUSSION {#jcla23251-sec-0014}
=============

This work was motivated by the discovery of m^6^A modification genes as critical cancer regulators and the emerging role of m^6^A gene SNPs in cancer susceptibility. Thus, we proposed a potential contributing role of m^6^A SNPs in Wilms tumor risk. Herein, we attempted to investigate whether *ALKBH5* gene SNPs could link to the risk of Wilms tumor. Our data suggested a weak association between *ALKBH5* gene SNPs and Wilms tumor risk in Chinese children. To date, this is the first report focusing on the association between the *ALKBH5* gene SNPs and Wilms tumor risk.

The m^6^A demethylases include FTO and ALKBH5, both of which belong to the AlkB family.[36](#jcla23251-bib-0036){ref-type="ref"} ALKBH5 was firstly found to have demethylation activity in 2013.[24](#jcla23251-bib-0024){ref-type="ref"} FTO‐mediated m^6^A demethylation generates two intermediates, N6‐hydroxymethyladenosine (hm^6^A) and N6‐formyladenosine (f^6^A), which were finally hydrolyzed into adenine.[37](#jcla23251-bib-0037){ref-type="ref"}, [38](#jcla23251-bib-0038){ref-type="ref"} Unlike FTO, ALKBH5 catalyzes the direct removal of m^6^A without generating an intermediate.[39](#jcla23251-bib-0039){ref-type="ref"} Silencing of *ALKBH5* led to the increase in the total m^6^A levels on RNA as well as the boost of RNAs exportation from the nucleus to the cytoplasm.[24](#jcla23251-bib-0024){ref-type="ref"} Moreover, *ALKBH5* also significantly affects RNA metabolism and the assembly of mRNA processing factors.[24](#jcla23251-bib-0024){ref-type="ref"} *ALKBH5* is critically implicated in the development and progression of several malignancies. Zhang et al[40](#jcla23251-bib-0040){ref-type="ref"} found that expression of *ALKBH5* was upregulated in glioblastoma stem‐like cells (GSCs). *ALKBH5* regulates *FOXM1* gene expression, consequently affecting GSC tumorigenesis. Enhanced *ALKBH5* induced by hypoxia decreases the level of methylated *NANOG* mRNA. The increased NANOG protein levels promote the enrichment of breast cancer stem cell (BCSC) population. Conversely, knockdown of *ALKBH5* impairs tumor formation in vivo by decreasing hypoxia‐induced NANOG expression and BCSC enrichment.[41](#jcla23251-bib-0041){ref-type="ref"} It was also reported that overexpression of *ALKBH5* promotes invasion and metastasis of gastric cancer by demethylating the lncRNA *NEAT1*.[42](#jcla23251-bib-0042){ref-type="ref"} Panneerdoss et al[43](#jcla23251-bib-0043){ref-type="ref"} revealed that *ALKBH5* exerts its pro‐tumorigenic role by regulating m^6^A levels of angiogenesis‐associated and epithelial‐mesenchymal transition transcripts. They provided evidence that collaboration among writers, erasers, and readers regulates cancer growth and progression. Although the significance of the m^6^A gene in cancer is highly appreciated, the study of m^6^A‐SNPs is a nascent field as yet.

*FTO*, as well as its SNPs, were revealed to be strongly associated with various human diseases, mainly obesity, and cancer.[44](#jcla23251-bib-0044){ref-type="ref"}, [45](#jcla23251-bib-0045){ref-type="ref"}, [46](#jcla23251-bib-0046){ref-type="ref"} Unlike *FTO*, information of *ALKBH5* SNPs was still limited. Only until recently has it begun to be realized that m^6^A‐SNPs in the *ALKBH5* account for genetic predisposition to complex traits, such as cancer. Du et al[30](#jcla23251-bib-0030){ref-type="ref"} reported that SNP rs12936694 in the *ALKBH5* gene plays a significant role in conferring to the risk of major depressive disorder in the Chinese Han population. A recent study has shown that 21 SNPs in the *ALKBH5* gene were significantly associated with the risk of rheumatoid arthritis in Asian and European populations.[31](#jcla23251-bib-0031){ref-type="ref"} Most recently, Meng et al performed the first case‐control study regarding m^6^A SNPs and cancer risk. Their study comprised of two stages, discovery stage with 1150 colorectal cancer cases and 1342 controls, and validation stage with 932 colorectal cancer cases and 966 controls. They comprehensively analyzed 240 SNPs in 20 m^6^A modification‐related genes. Among them, only the *SND1* gene rs118049207 contributes to the development of colorectal cancer in the Chinese population. They circumstantiated that rs118049207 change the mRNA of *SND1* gene, and then lead to m^6^A level alteration. SNPs rs2124370, rs8400, rs9899249, rs9913266, and rs2925137 in the *ALKBH5* gene were not associated with colorectal cancer risk.[32](#jcla23251-bib-0032){ref-type="ref"} Given that *FTO*‐SNPs are involved in cancer risk, we have reason to believe that *ALKBH5* gene SNPs exert a similar role. Due to extremely low prevalence, studies specifically in this area of Wilms tumor have not been conducted. Thus, it is of a great necessity to investigate the association between *ALKBH5* gene SNPs and the risk of Wilms tumor. The current clinical analysis provided only a weak impact of *ALKBH5* gene SNPs on susceptibility to Wilms tumor. We speculate the insufficient statistical power caused by the moderate sample size, relative weak effects of single polymorphism, and the influence of other potential pertinent factors may work together to generate such results. To be noted, positive associations were only detected for rs1378602 AG/AA genotypes and 1‐2 protective genotypes under certain subgroups. These data observed in this study are in accordance with the perception of cancer susceptibility, which represents a genetic attribute that modify the possible cancer risk under the influence of environmental conditions or lifestyles. Therefore, significant associations observed here needed to be detected in a larger study with other factors included. Alternatively, these results could be because of chance, which call for larger and validation studies.

The strengths of our study include its good design, multicentric analysis, and relatively large sample size. However, we cannot neglect its accompanied shortcomings. First, although our study was large, the stratified analyses were still limited in power due to the relatively small sample size. The significant findings might be chance observations (FPRP values larger than 0.2 at the prior probability level of 0.1). Therefore, the conclusion obtained here must be viewed as preliminary and needs to be confirmed. Second, all the included participants were Chinese based population. The single population here limits the applicability of the findings to other ethnicities. Last, the current study focuses on only the relationship of m^6^A‐SNPs with cancer risk. The specific mechanisms underlying the effect of the abovementioned m^6^A‐SNPs genotypes on cancer risk should be investigated.

To the best of our knowledge, this is the first large‐scale and multi‐center evaluation of SNPs of key candidate genes involved in the m^6^A pathway and Wilms tumor susceptibility. The observed association should be further validated in another well‐designed analysis with other larger ethnicities.
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